InspireMD announces commercial launch of the CGuard Prime in the U.S.

InspireMD (NSPR) announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following its premarket application, or PMA, approval from the FDA. The CGuard Prime was engineered specifically to minimize both early and late embolism risk by effectively trapping potential emboli against the arterial wall while preserving external carotid artery perfusion. This innovative device features three key advantages: First, a dual layer design that combines the largest open-cell frame with the smallest mesh pore size available. Second, the MicroNet(TM), a bio-stable mesh crafted from a single 20 mum Polyethylene Terephthalate strand that traps and seals thrombus and plaque against the vessel wall to prevent embolization. Third, SmartFit technology eliminates the need for tapered versions while ensuring precise vessel wall apposition.